InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,022.00
(
1.61%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.52
(
1.28%
)
Bitcoin
66,113.91
(
-1.11%
)
Post# of 251571
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: cooldrinkh2o post# 180680

Thursday, 07/24/2014 1:08:04 PM

Thursday, July 24, 2014 1:08:04 PM

Post# of 251571
Give credit to whoever designed the trial, and PBYI seeing through the trial to success, plus definite credit for seeing potential of Neratinib because most people are skeptical of a drug discarded by big pharma. I always argued against that line of thinking by emphasizing on merit of drug itself:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76636074

HERA trial showed Herceptin 2-year adjuvant no better than 1-year adjuvant, HR=0.99:

http://www.ncbi.nlm.nih.gov/pubmed/23871490

Anyway, Neratinib for extended adjuvant had really good HR, you have to admit that. We'll see about safety profile from this large trial soon, maybe at SABCS?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up